anti-CD40L antibody frexalimab which is in mid-stage testing for multiple sclerosis, and SAR441566, an orally-active TNF blocker that Sanofi thinks could be the biggest drug it has ever developed.

Other CD40L-directed therapies in the industry pipeline include Sanofi's frexalimab – in phase 3 for multiple sclerosis and phase 2 for SLE and type 1 diabetes – and Novartis' iscalimab ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In February, phase II trial data showed that frexalimab, an investigational second-generation CD40 ligand inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing MS. At ...

Royalty Pharma's Q3 results met expectations, with a modest 2024 outlook increase, driven by strong portfolio performance and new royalty acquisitions. The CF franchise remains a key cash cow ...

Please find enclosed communication for the attention of the shareholders of the Company for Apportionment of Cost of Acquisition of Equity Shares of Sanofi India Limited and Sanofi Consumer Healthcare ...

Dimitrios Karussis, Department of Neurology, Laboratory of Neuroimmunology and the Agnes Ginges Center for Neurogenetics, Hadassah-Hebrew University Center, Jerusalem, Ein-Karem, IL-91120, Israel ...

Uveitis is uncommon in patients with multiple sclerosis (MS), but the link between the two entities is clearly established. While a common etiology or pathologic process remains unknown, shared ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 14,385.85 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...